Your browser doesn't support javascript.
loading
Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial.
Clarke, David K; Xu, Rong; Matassov, Demetrius; Latham, Theresa E; Ota-Setlik, Ayuko; Gerardi, Cheryl S; Luckay, Amara; Witko, Susan E; Hermida, Luz; Higgins, Terry; Tremblay, Marc; Sciotto-Brown, Susan; Chen, Tracy; Egan, Michael A; Rusnak, Janice M; Ward, Lucy A; Eldridge, John H.
Afiliación
  • Clarke DK; Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA. Electronic address: dclarke@profectusbiosciences.com.
  • Xu R; Department of Immunology, Profectus BioSciences, Pearl River, NY, USA.
  • Matassov D; Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA.
  • Latham TE; Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA.
  • Ota-Setlik A; Department of Immunology, Profectus BioSciences, Pearl River, NY, USA.
  • Gerardi CS; Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA.
  • Luckay A; Department of Immunology, Profectus BioSciences, Pearl River, NY, USA.
  • Witko SE; Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA.
  • Hermida L; Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA.
  • Higgins T; Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA.
  • Tremblay M; Department of Quality Assurance, Profectus BioSciences, Pearl River, NY, USA.
  • Sciotto-Brown S; Department of Regulatory Affairs, Profectus BioSciences, Pearl River, NY, USA.
  • Chen T; Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA.
  • Egan MA; Bill and Melinda Gates Medical Research Institute, Cambridge, MA, USA.
  • Rusnak JM; Joint Project Manager for Chemical, Biological, Radiological and Nuclear Medical, Fort Detrick, MD, USA.
  • Ward LA; Joint Project Manager for Chemical, Biological, Radiological and Nuclear Medical, Fort Detrick, MD, USA.
  • Eldridge JH; Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA; Department of Immunology, Profectus BioSciences, Pearl River, NY, USA.
Lancet Infect Dis ; 20(4): 455-466, 2020 04.
Article en En | MEDLINE | ID: mdl-31952923
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Seguridad / Glicoproteínas / Fiebre Hemorrágica Ebola / Vacunas contra el Virus del Ébola / Ebolavirus / Inmunogenicidad Vacunal Tipo de estudio: Clinical_trials Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Seguridad / Glicoproteínas / Fiebre Hemorrágica Ebola / Vacunas contra el Virus del Ébola / Ebolavirus / Inmunogenicidad Vacunal Tipo de estudio: Clinical_trials Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2020 Tipo del documento: Article